Claims
- 1. A compound according to formula I:
- 2. A compound according to claim 1, wherein R is —(CH2)nR1 and R1 is a C3-G6 aryl optionally substituted at one or more positions with a group selected from: Cl; F; NO2; I; Br; a C1-C3 alkyl; and a C1-C3 alkoxy and wherein n=0-3.
- 3. A compound according to formula II:
- 4. A compound according to claim 3, wherein R is —(CH2)qR5 wherein q=0-3 and R5 is a C3-C6 aryl optionally substituted at one or more positions with a group selected from: a straight or branched C1-C3 alkyl; a C1-C3 alkoxy; I; Cl; CN; F; NO2; —(CH2)rCF3, wherein r=0-3; and —C(O)R6, wherein R6 is a C1-C3 alkyl.
- 5. A compound according to formula III:
- 6. A compound according to formula IV:
- 7. The compound of claim 6, wherein R8 is H and R9 together with N form a ring selected from the group consisting of a phthalamide ring; a pyrrolidine ring; a piperidine ring; a tetrahydroquinoline ring; and an indole ring; said ring structure being optionally substituted at one or more positions with a group selected from: a C1-C3 alkyl; a C1-C3 alkoxy; Cl; F; NO2; and CF3
- 8. The compound of any one of claims 1-7, wherein X=H and Y=H.
- 9. A pharmaceutical composition comprising a compound according to any one of claims 1, 3, 5, or 6.
- 10. A method of treating a patient for pain, comprising administering to said patient an effective amount of the pharmaceutical compound of claim 9.
- 11. A method of treating a patient for Parkinson's disease, comprising administering an effective amount of the pharmaceutical composition of claim 9.
- 12. A method of treating a patient for cancer, comprising administering an effective amount of the pharmaceutical compound of claim 9.
- 13. A method of treating a patient for AIDS, comprising administering an effective amount of the pharmaceutical compound of claim 9.
- 14. A compound selected from the group consisting of:
(1S,2S)-2-methoxy-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(ethoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(isopropoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(1-propenyloxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(2-trimethylsilyl-ethoxy) 1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-benzyloxy-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-methoxybenzyloxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(2,2,2-trifluoro-ethoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-6,7-difluoro-2-methoxy-1,2-dihydro-naphthalen-1-ol; (1S,2S)-6-methoxy-5,6-dihydro-naphthol[2,3-d][1,3]dioxol-5-ol; (1S,2S)-6,7-dibromo-2-methoxy-5,8-dimethyl-1,2-dihydro-naphthalen-1-ol; (1R*,2R*)-acetic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl-ester; (1R*,2 R*)-propionic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl-ester; (1R,2R)-benzoic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl-ester; (1R*,2R*)-formic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl-ester; (1R*,2R*)-2-methyl acrylic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl-ester; (1R*,2R*)-malonic acid ethyl ester (1-hydroxy-1,2-dihydro-naphthalen-2-yl) ester; (1R*,2R*)-malonic acid (1-tert-butylbimethylsiloxy-1,2-dihydro-naphthalen-2-yl) ethyl ester; (1S*,2S*)4-tert-butyldimethylsiloxy-1,4-dihydro-naphthalen-2-yl) acetic acid ethyl ester; (1R,2R)-2-(1-hydroxy-1,2-dihydro-naphthalen-2-yl)-isoindole-1,3-dione; (1S,2S)-N-(1-hydroxy-1,2-dihydro-naphthalen-2-yl)-benzene sulfonamide; (1R*,2R*)-2-pyrrolidin-1-yl-1,2-dihydro-naphthalen-1-ol; (1R*,2R*)-2-piperidin-1-yl-1,2-dihydro-naphthalen-1-ol; (1R,2R)-2-(3,4-dihydro-2H-quinolin-1-yl)-1,2-dihydro-naphthalen-1-ol; (1R,2R)-2-(methyl-phenyl-amino)-1,2-dihydro-naphthalen-1-ol; (1R*,2R*)-2-benzylamino-1,2-dihydro-naphthalen-1-ol; (1R*,2R*)-2-(4-methoxy-benzylamino)-1,2-dihydro-naphthalen-1-ol; (1R,2R)-2-indol-1-yl-1,2-dihydro-naphthalen-1-ol; (1S*,2R*)-2-(hydroxy-1,2-dihydro-naphthalen-2-yl)malonic acid dimethyl ester; (1S,2S)-2-phenoxy-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-nitrophenoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-cyanophenoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-acylphenoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-trifluoromethylphenoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-fluorophenoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-chlorophenoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-iodophenoxy)-1,2-dihydro-naphthalen-1-ol; (1R,2R)-2-(4-bromo-phenoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-methylphenoxy)-1,2-dihydro-naphthalen-1-ol; (1S,2S)-2-(4-methoxyphenoxy)-1,2-dihydro-naphthalen-1-ol; and (1S,2S)-2-(2-bromophenoxy)-1,2-dihydro-naphthalen-1-ol; 4-methyl-N-[(1R,2S)-2-(1-piperidinyl)-1,2-dihydro-1-naphthalenyl]benzenesulfonamide; N-[(1R,2S)-2-(3,4-dihydro-1 (2H)-quinolinyl)-1,2-dihydro-1-naphthalenyl]-4-methylbenzenesulfonamide; N-[(1R,2S)-2-(3,4-dihydro-2(1H)-isoquinolinyl)-1,2-dihydro-1-naphthalenyl]-4-methylbenzenesulfonamide; N-[(1R,2S)-2-(1H-indol-1-yl)-1,2-dihydro-1-naphthalenyl]-4-methylbenzenesulfonamide; (1R,25)-2-methoxy-N-phenyl-1,2-dihydro-1-naphthalenamine; tert-butyl(1R,2S)-2-methoxy-1,2-dihydro-1-naphthalenylcarbamate; N-[(1R,2S)-2-methoxy-1,2-dihydro-1-naphthalenyl]-2-(trimethylsilyl)ethanesulfonamide; N,4-dimethyl-N-[(1R,2S)-2-(1-pyrrolidinyl)-1,2,3,4-tetrahydro-1-naphthalenyl]-benzenesulfonamide; N,4-dimethyl-N-[(1R,2S)-2-(1-pyrrolidinyl)-1,2-dihydro-1-naphthalenyl]-benzenesulfonamide; N-hydroxy-4-({methyl[(1R,2S)-2-(1-pyrrolidinyl)-1,2-dihydro-1-naphthalenyl]amino}sulfonyl)-N-oxobenzenaminium; N-methyl-4-nitro-N-[(1R,2S)-2-(1-pyrrolidinyl)-1,2-dihydro-1-naphthalenyl]-benzenesulfonamide; (1R,2S)-N-methyl-2-(1-pyrrolidinyl)-1,2,3,4-tetrahydro-1-naphthalenamine; N-[(1R,2S)-2-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl]-4-methylbenzenesulfonamide; N-[(1R,2S)-2-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl]-4-methylbenzenesulfonamide; 4-methyl-N-[(1R,25)-2-phenoxy-1,2,3,4-tetrahydro-1-naphthalenyl]benzenesulfonamide; (1R,25)-1-{[(4-methylphenyl)sulfonyl]aminol}-1,2,3,4-tetrahydro-2-naphthalenyl acetate; (1R,2S)-1-{[(4-methylphenyl)sulfonyl]amino}-1,2-dihydro-2-naphthalenyl benzoate; (1R,2S)-1-{[(4-methylphenyl)sulfonyl]amino}-1,2-dihydro-2-naphthalenyl pivalate; N-[(1R,2S)-2-methoxy-1,2-dihydro-1-naphthalenyl]-2-(trimethylsilyl)ethanesulfonamide; tert-butyl (1R,2S)-2-methoxy-1,2-dihydro-1-naphthalenylcarbamate; and 4-nitro-N-[(1R,2S)-2-(1-pyrrolidinyl)-1,2-dihydro-1-naphthalenyl]benzenesulfonamide.
- 15. A pharmaceutical composition comprising a compound according to claim 14.
- 16. A method of treating a patient for pain, comprising administering to said patient an effective amount of the pharmaceutical of claim 15.
- 17. A method of treating a patient for Parkinson's Disease, comprising administering to said patient an effective amount of the pharmaceutical composition of claim 15.
- 18. A method of treating a patient for cancer, comprising administering to said patient an effective amount of the pharmaceutical composition of claim 15.
- 19. A method of treating a patient for AIDS, comprising administering to said patient an effective amount of the pharmaceutical composition of claim 15.
- 20. A process for preparing a compound according to formula I of claim 1, comprising reacting a compound of formula ROH with a compound of formula V:
- 21. The process of claim 20, wherein said phosphine ligand is selected from the group consisting of: DPPF; (R)-(S)-BPPFA; and (R)-(S)-PPF-PtBu2.
- 22. A process for preparing a compound according to formula II of claim 3, comprising reacting a compound of formula ROH with a compound of formula V:
- 23. The process of claim 22, wherein said phosphine ligand is (S)-(R)-PPF-PtBu2.
- 24. A process for preparing a compound according to formula III of claim 5, comprising:
(a) preparing a compound of formula I according to the process of claim 20; and (b) reacting the compound formed in step (a) with a salt of tert-butyldimethylsilylic acid.
- 25. A process for preparing a compound of formula IV according to claim 6, comprising reacting a compound of formula R9—(CH2)tNHR8 with a compound of formula V
- 26. The process of claim 25, wherein said phosphine ligand is selected from the group consisting of: DPPF; (R)—(S)-BPPFA; and (R)—(S)-PPF-PtBu2.
- 27. The process of claim 26, wherein R9 together with N form a ring selected from the group consisting of: a phthalamide ring; a pyrrolidine ring; a piperidine ring; a tetrahydroquinoline ring; and an indole ring; said ring structure being optionally substituted at one or more positions with a group selected from: a C1-C3 alkyl; a C1-C3 alkoxy; Cl; F; NO2; and CF3.
- 28. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-methoxy-1,2-dihydro-naphthalen-1-ol, and said compound of formula ROH is methanol.
- 29. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(ethoxy)-1,2-dihydro-naphthalen-1-ol, and said compound of formula ROH is ethanol.
- 30. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-isopropoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is isopropanol.
- 31. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-1-propenyloxy)-1,2-dihydro-naphthalen-1-ol, and said compound of formula ROH is allyl alcohol.
- 32. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(2-trimethylsilyl-ethoxy)-1,2-dihydro-naphthalen-1-ol, and said compound of formula ROH is trimethylsilylethanol.
- 33. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-benzyloxy-1,2-dihydro-naphthalen-1-ol, and said compound of formula ROH is benzylalcohol.
- 34. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-4-methoxybenzyloxy-1,2-dihydro-naphthalen-1-ol, and said compound of formula of ROH is anisylalcohol.
- 35. The method of claim 22, wherein said compound of formula II is (1S,2S)-2-(2,2,2-trifluoro-ethoxy)-1,2-dihydro-naphthalen-1-ol, and said compound of formula ROH is trifluoroethanol.
- 36. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is hexafluoroisopropanol.
- 37. The process of claim 22, wherein said compound of formula II is (1S,2S)-6,7-difluoro-2-methoxy-1,2-dihydro-naphthalen-1-ol and wherein said compound of formula ROH is methanol.
- 38. The method of claim 22, wherein said compound of formula II is (1S,2S)-6-methoxy-5,6-dihydro-naphtho[2,3-d][1,3]dioxol-5-ol and wherein said compound of formula ROH is methanol.
- 39. The method of claim 22, wherein said compound of formula II is (1S,2S)-6,7-dibromo-2-methoxy-5,8-dimethyl-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is methanol.
- 40. The process of claim 20, wherein said compound of formula I is (1R*,2R*)-acetic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl ester and said compound of formula ROH is acetic acid.
- 41. The process of claim 20, wherein said compound of formula I is (1R*,2R*)-propionic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl ester and said compound of formula ROH is propionic acid.
- 42. The process of claim 20, wherein said compound of formula I is (1R,2R)-benzoic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl-ester and said compound of formula ROH is benzoic acid.
- 43. The process of claim 20, wherein said compound of formula I is (1R*,2R*)-formic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl-ester and said compound of formula ROH is formic acid.
- 44. The process of claim 20, wherein said compound of formula I is (1R*,2R*)-2-methyl acrylic acid 1-hydroxy-1,2-dihydro-naphthalen-2-yl-ester and said compound of formula ROH is methacrylic acid.
- 45. The process of claim 20, wherein said compound of formula I is (1R*,2R*)-malonic acid ethyl-ester (1-hydroxy-1,2-dihydro-naphthalen-2-yl) ester and said compound of formula ROH is ethyl malonic acid.
- 46. The method of claim 24, wherein said compound of formula III is (1R*,2R*)-malonic acid (1-tert-butyldimethylsiloxy-1,2-dihydro-naphthalen-2-yl) ester ethyl ester and said compound of formula ROH is tert-butyldimethylsilylic acid.
- 47. The method of claim 22, wherein said compound of formula II is (1S,2S)-2-phenoxy-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is phenol.
- 48. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(4-nitrophenoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is 4-nitrophenol.
- 49. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(4-cycanophenoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is 4-trifluoromethylphenyl.
- 50. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(4-acylphenoxy)-1,2,-dihydro-naphthalen-1-ol and said compound of formula ROH is 4-hydroxyacetophenone.
- 51. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(4-trifluoromethylphenoxy)-1,2,-dihydro-naphthalen-1-ol and said compound of formula ROH is 4-trifluoromethylphenyl.
- 52. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(4-fluorophenoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is 4-fluorophenol.
- 53. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(4-chlorophenoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is 4-chlorophenol.
- 54. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(4-iodophenoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is 4-iodophenol.
- 55. The process of claim 20, wherein said compound of formula I is (1R,2R)-2-(4-bromo-phenoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is p-bromophenol.
- 56. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(4-methylphenoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is p-cresol.
- 57. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(4-methoxyphenoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is 4-methoxyphenol.
- 58. The process of claim 22, wherein said compound of formula II is (1S,2S)-2-(2-bromophenoxy)-1,2-dihydro-naphthalen-1-ol and said compound of formula ROH is 2-bromophenol.
- 59. The process of claim 25, wherein said compound of formula IV is (1R,2R)-2-(1-hydroxy-1,2-dihydro-naphthalen-2-yl) isoindole-1,3-dione and said compound of formula R9—(CH2)sNHR8 is phthalimide.
- 60. The process of claim 25, wherein said compound of formula TV is (1R*,2R*)-2-pyrrolidin-1-yl-1,2-dihydro-naphthalen-1-ol and said compound of formula R9-(CH2)sNHR8 pyrrolidine.
- 61. The process of claim 25, wherein said compound of formula IV is (1R*,2R*)-2-piperidin-1-yl-1,2-dihydro-naphthalen-1-ol and said compound of formula R9—(CH2)sNHR8 is piperidine.
- 62. The process of claim 25, wherein said compound of formula IV is (1R,2R)-2-(3,4-dihydro-2H-quinolin-1-yl)-1,2-dihydro-naphthalen-1-ol and said compound of formula R9—(CH2)sNHR8 is tetrahydroisoquinoline.
- 63. The process of claim 25, wherein said compound of formula IV is (1R,2R)-2(methyl-phenyl-amino)-1,2-dihydro-naphthalen-1-ol and said compound of formula R9—(CH2)sNHR8 is N-methylaniline.
- 64. The process of claim 25, wherein said compound of formula IV is (1R*,2R*)-2-benzylamino-1,2-dihydro-naphthalen-1-ol and said compound of formula R9—(CH2)sNHR8 is benzylamine.
- 65. The process of claim 25, wherein said compound of formula IV is (1R*,2R*)-2-(4-methoxy-benzylamino)-1,2-dihydro-naphthalen-1-ol and said compound of formula R9—(CH2)sNHR8 is p-methoxybenzylamine.
- 66. The process of claim 25, wherein said compound of formula IV is (1R,2R)-2-indol-1-yl-1,2-dihydro-naphthalen-1-ol and said compound of formula R9—(CH2)sNHR8 is indole.
- 67. A process for preparing (1S,2S)-N-(1-hydroxy-1,2-dihydro-naphthalen-2-yl)-benzene sulfonamide, comprising reacting oxabenzonorbornadiene with benzenesulfonamide, wherein said reaction is catalyzed by [Rh(COD)Cl]2 in the presence of a phosphine ligand.
- 68. A process for preparing (1S*,2R*)-2-(hydroxy-1,2-dihydro-naphthalen-2-yl)malonic acid dimethyl ester, comprising reacting oxabenzonorbornadiene with dimethyl malonate, wherein said reaction is catalyzed by [Rh(COD)Cl]2 in the presence of a phosphine ligand.
Priority Claims (1)
| Number |
Date |
Country |
Kind |
| 9903930-7 |
Oct 1999 |
SE |
|
FIELD OF THE INVENTION
[0001] The present invention is directed to methods for chemically synthesizing compounds containing a hydronaphthalene ring structure. It encompasses the compounds made by the methods, pharmaceutical preparations containing the compounds, and methods for treating patients using these pharmaceutical preparations.
Divisions (1)
|
Number |
Date |
Country |
| Parent |
09763759 |
Feb 2001 |
US |
| Child |
10317183 |
Dec 2002 |
US |